Dr Joy Ho discusses the first clinical results from the phase I inMMyCAR study evaluating KLN-1010, an investigational off-the-shelf in vivo anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma. She highlights early MRD-negative responses, in vivo CAR-T expansion without lymphodepletion or apheresis, and a manageable safety profile with limited cytopenias and no observed neurotoxicity in the first treated patients.